Navigation Links
Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Date:9/1/2011

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences:

  • R.W. Baird Health Care Conference on Wednesday, September 7, 2011 at 12:45 p.m. Eastern Time at the New York Palace in New York.
  • Morgan Stanley Global Healthcare Unplugged Conference on Tuesday, September 13, 2011 at 8:00 a.m. Eastern Time at the Grand Hyatt in New York.
  • UBS Global Life Sciences Conference on Monday, September 19, 2011 at 12:00 p.m. Eastern Time at the Grand Hyatt in New York.
  • JMP Securities Healthcare Conference on Tuesday, September 27, 2011 at 4:00 p.m. Eastern Time at the St. Regis in New York.

Live audio webcasts of these presentations will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of these presentations will be available at the same location for 30 days following the meeting.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
3. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
7. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
8. Optimer Pharmaceuticals Expands Senior Management Team
9. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
10. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... MADISON, N.J., Jan. 6, 2012 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today the ... Health System to acquire S.E.D. Medical Laboratories. Under the ... assets of S.E.D. Medical Laboratories and will manage in-patient ...
... 2012 In preparation for meetings starting Monday, ... scheduled for 10:00 a.m. Thursday, January 12 at ... Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the fourth quarter 2011:       -Approximately 935-950 ...
Cached Medicine Technology:Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories 2Questcor Pharmaceuticals Reports Strong Finish to 2011 2Questcor Pharmaceuticals Reports Strong Finish to 2011 3Questcor Pharmaceuticals Reports Strong Finish to 2011 4Questcor Pharmaceuticals Reports Strong Finish to 2011 5Questcor Pharmaceuticals Reports Strong Finish to 2011 6
(Date:9/18/2014)... expect to pay higher employee contributions for their health ... officers about the impact of the Patient Protection and ... conducted by the Darla Moore School of Business at ... Patrick Wright, a professor in strategic human resource management, ... Officers. The survey is distributed to more than 560 ...
(Date:9/18/2014)... guidelines recommending that elderly men should not be routinely ... according to a new study led by researchers at ... letter online in JAMA Internal Medicine , focused ... to test for prostate cancer., "We found that the ... of elderly men in particular has been minimal at ...
(Date:9/18/2014)... For years, neuroscientists have been trying to develop tools ... circuitry in actionfrom the first moment a neuron fires ... get this complete picture, neuroscientists are working to develop ... Researchers at Caltech have developed one such tool that ... a living organism. , The worka collaboration between Viviana ...
(Date:9/18/2014)... With the swift industrial development of ... as smart phones, tablets and PDAs, a complete change ... devices are viewed these days. From only being used ... a mode for creating and delivering content while on ... , The complete makeover of this (mobile) ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... the market , WEDNESDAY, Oct. 14 (HealthDay News) -- Peter ... Management and Budget, is reported to drink so much tea, ... see if his body could metabolize his voluminous intake of ... suited to the task, and Orszag can easily go about ...
... Calif., Oct. 14 Bionovo, Inc. (Nasdaq: BNVI ) ... Medicine and Co-Director of the Women,s Cancer Program at the ... Tripathy is a world renowned leader and researcher in the ... have one of the world,s foremost authorities in the area ...
... ... Group ,as key part of innovative quit smoking program , ... Auckland, New Zealand (Vocus) October 14, 2009 ... Health, has recently marked one year of successful operation with HSAGlobal,s STOMP text message-based ...
... , ... people who suffer from sleeping problems report better sleep with Gene-Eden, a natural supplement that ... ... with users of the natural antiviral Gene-Eden. Analysis of the interviews revealed that the users ...
... (NYSE: CNO ) announced today that, in compliance with ... access to information, it will post certain important information on ... The materials consist of a Current Report on Form ... Securities Exchange Commission (the "SEC") after 5:30 p.m. on Tuesday, ...
... , PORTLAND, Ore., Oct. 13 The following is ... of Regence BlueCross BlueShield, regarding the Senate Finance Committee vote ... , "Regence continues to be cautiously optimistic that an economically ... Today,s vote is an important step toward ensuring long-term ...
Cached Medicine News:Health News:Are Commercial Genetic Tests Worth Taking? 2Health News:Are Commercial Genetic Tests Worth Taking? 3Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 2Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 3Health News:First Commercial Text Messaging Smoking Cessation Service Marks One Year of Operation 2Health News:First Commercial Text Messaging Smoking Cessation Service Marks One Year of Operation 3Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 2Health News:Users of Gene-Eden, a Natural Antiviral, Report less Sleeping Problems in a Recent Study 3Health News:Conseco Announces Availability of Important Information on its Website 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: